Work

Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

Year: 2026

Type: article

Study design: Clinical Trial

Source: Journal of Clinical Oncology

DOI: 10.1200/jco-25-01047

Authors: Oleg Gluz, Ulrike A. Nitz, Matthias Christgen, Sherko Kuemmel, Johannes Holtschmidt, Johannes Schumacher, Philip Raeth, Andreas D. Hartkopf, Kerstin Luedtke-Heckenkamp, Marianne Just, Raquel von Schumann, Silke Polata, Timo Schinkoethe, Monika K. Graeser, Ronald Kates, Rachel Wuerstlein, Nadia Harbeck

Institutions: Evangelisches Krankenhaus Bethesda Mönchengladbach, Women‘s Healthcare Group, Medizinische Hochschule Hannover, Kliniken Essen-Mitte, Bundeskriminalamt, University of Tübingen, Ludwig-Maximilians-Universität München, Witten/Herdecke University

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7161541176

FWCI: 5.267

Cites: 12

Cited by: 2

Related to: